Skip to main content

Table 3 The RAS mutation status is maintained throughout disease course

From: Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing

Case ID# RAS
Mut.
PT syn
M[HEP] 1
syn
M[HEP] 2
syn
M[PUL] 1
syn
M[PUL] 2
met
M[HEP] 1
met
M[PUL] 1
met
M[PUL] 2
met
M[PUL] 3
1 KRAS
G12D
55.59 97.28      16.77   
2 KRAS
G12V
53.59 89.98   47.32 32.82     
3 KRAS
G12V
21.92      45.26 0 and
21.22
34  
4 WT 0 0     0 0   
5 KRAS
G12A
24.18 9.7a   17.72 36.04     
6 KRAS
G12V
22.85      0 26.73   
7 WT 0 0     0, 0    
8 KRAS
G13D
34.16 50.44   31.43    12.85   
9 WT 0 0      0 0  
10 WT 0      0 0   
11 WT 0 0      0   
12 KRAS
G12A
99.74 56.72      34.15 19.63  
13 KRAS
G12D, G12V
19.83 (G12D) 16.44 (G12V)   5.62a and 25.72
(G12V)
     
14 NRAS Q61R 44.31 66.91 and 44.74   46.17      
  1. The table summarizes the RAS status and mutated allele frequency (%) throughout the disease course of 9/14 mutated CRC cases. If two metastatic lesions were resected at the same time, the RAS status is given for both
  2. a= sequence variant detected at below 10 % allele frequency